SCHEMBL29951145

SCHEMBL29951145

Cc1cc(N)c(C=O)c(C)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.37
NR4A2 P43354 2/20 0.37
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35
KDM4E B2RXH2 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
ALDH1A1 P00352 4/20 0.33
MAPT P10636 2/20 0.33
GAA P10253 1/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
MMP1 P03956 1/20 0.33
MMP9 P14780 1/20 0.33
ALOX15 P16050 1/20 0.33
BLM P54132 1/20 0.33
GNG2 P59768 1/20 0.33
GNB1 P62873 1/20 0.33
ERN1 O75460 1/20 0.33
APAF1 O14727 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3175002 1.00 NCF1 (0.37) NCF1NR4A2NOS3NOS1NOS2
SCHEMBL31353512 0.80 POLB (0.42) NCF1NR4A2KDM4ETDP1ALDH1A1
SCHEMBL29951488 0.78 CYP1A2 (0.38) KDM4ETDP1ALDH1A1MAPTGAA
SCHEMBL6160521 0.78 CYP1A2 (0.38) KDM4ETDP1ALDH1A1MAPTGAA
SCHEMBL25083506 0.75 ALDH1A1 (0.41) NR4A2KDM4ETDP1ALDH1A1MAPT
SCHEMBL29957337 0.75 ALDH1A1 (0.41) NR4A2KDM4ETDP1ALDH1A1MAPT
SCHEMBL7276962 0.74 NOS2 (0.46) NOS3NOS1NOS2KDM4EMAPT
SCHEMBL18510117 0.72 ERN1 (0.44) KDM4ETDP1ALDH1A1MAPTERN1
SCHEMBL16864240 0.71 NOS3 (0.35) NR4A2NOS3NOS1NOS2KDM4E
SCHEMBL8328225 0.71 BACE1 (0.41) NOS3NOS1NOS2ALDH1A1ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109715-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) 2026-04-23 US disclosed
EP-4600246-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE Public University Corporation Yokohama City University (JP) 2025-08-13 EP disclosed
WO-2024075696-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE 公立大学法人横浜市立大学 2024-04-11 WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109715-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE SMG1, RACK1, TIA1 NCF1 849/4885NR4A2 2678/4885NOS3 2341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.